Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Csl Ltd ADR (CSLLY)

Csl Ltd ADR (CSLLY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
76.7400 -0.3200 (-0.42%) 04/17/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 76.7400 unch (unch) 15:58 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
74.7300
Day High
77.0000
Open 76.4500
Previous Close 77.0600 77.0600
Volume 59,800 59,800
Avg Vol 131,295 131,295
Stochastic %K 59.65% 59.65%
Weighted Alpha -18.17 -18.17
5-Day Change +2.8500 (+3.86%) +2.8500 (+3.86%)
52-Week Range 70.2200 - 109.0000 70.2200 - 109.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 74,316,856
  • Shares Outstanding, K 968,424
  • Annual Sales, $ 14,800 M
  • Annual Income, $ 2,642 M
  • EBIT $ 0 M
  • EBITDA $ 4,750 M
  • 60-Month Beta 0.80
  • Price/Sales 5.04
  • Price/Cash Flow 19.37
  • Price/Book 3.84
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield 1.28 (1.66%)
  • Most Recent Dividend 0.600 on 03/11/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.2200 +9.29%
on 04/09/25
Period Open: 79.7700
82.0000 -6.41%
on 04/02/25
-3.0300 (-3.80%)
since 03/17/25
3-Month
70.2200 +9.29%
on 04/09/25
Period Open: 86.1600
89.6900 -14.44%
on 01/30/25
-9.4200 (-10.93%)
since 01/17/25
52-Week
70.2200 +9.29%
on 04/09/25
Period Open: 87.9600
109.0000 -29.60%
on 08/28/24
-11.2200 (-12.76%)
since 04/17/24

Most Recent Stories

More News
New Strong Sell Stocks for February 12th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Ares Management Corporation ARES is an alternative asset manager. The Zacks Consensus Estimate for its current year earnings has...

ARES : 141.24 (+1.17%)
CABGY : 27.4800 (+0.62%)
CSLLY : 76.7400 (-0.42%)
3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

GSK : 35.93 (+1.58%)
CSLLY : 76.7400 (-0.42%)
SNY : 50.90 (+0.67%)
CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple...

CSL : 353.27 (+1.45%)
CSLLY : 76.7400 (-0.42%)
Why CSL Ltd Stock Could Be Worth a Look

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

BLUE : 4.14 (-0.24%)
NVS : 110.86 (+1.17%)
ARCT : 10.53 (+2.23%)
CSL : 353.27 (+1.45%)
CSLLY : 76.7400 (-0.42%)
Why Arcturus Therapeutics Stock Is Skyrocketing Today

Investors are applauding Arcturus' collaboration with CSL.

CSL.AX : 239.350 (-1.05%)
ARCT : 10.53 (+2.23%)
CSLLY : 76.7400 (-0.42%)
Finalization of Vifor Pharma acquisition

Regulatory News:

CSL.AX : 239.350 (-1.05%)
OTC.VN : 0.275 (-5.17%)
CSLLY : 76.7400 (-0.42%)
uniQure announces closing of commercialization and license agreement with CSL Behring

Upfront payment of $450 million due to uniQure by May 13, 2021

QURE : 13.00 (+38.45%)
ASX : 8.08 (-1.58%)
CSLLY : 76.7400 (-0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived...

See More

Key Turning Points

3rd Resistance Point 79.8533
2nd Resistance Point 78.4267
1st Resistance Point 77.5833
Last Price 76.7400
1st Support Level 75.3133
2nd Support Level 73.8867
3rd Support Level 73.0433

See More

52-Week High 109.0000
Fibonacci 61.8% 94.1860
Fibonacci 50% 89.6100
Fibonacci 38.2% 85.0340
Last Price 76.7400
52-Week Low 70.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro